ResMed CEO Michael J. Farrell Executes 10b5-1 Option Exercise and Sale

Transaction Analysis: ResMed Inc. (NYSE: RMD)

Overview

On October 7, 2026, ResMed Chairman and CEO Michael J. Farrell executed a planned option exercise and subsequent sale of 4,991 shares of common stock. The sale grossed approximately $1.13 million at a volume-weighted average price of $226.3349 per share.

Transaction Breakdown

• Option Exercise: 4,991 stock options exercised at an exercise price of $146.34 per share (expiring November 21, 2026).
• Open Market Sale: 4,991 shares sold at a weighted average price of $226.3349 (trade prices ranged from $222.2135 to $227.5810).
• Gross Proceeds: $1,129,637.49
• Net Profit (before taxes/fees): Approximately $399,250.05

Context and Significance

• Trading Significance: Low.
• Pre-Scheduled Plan: The transaction was carried out pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on October 31, 2024.
• Impending Expiration: The exercised options were nearing their expiration date of November 21, 2026, making this a routine exercise-and-sell transaction.
• Holdings Impact: The sale represents less than 1.1% of Farrell's direct holdings. Following the transaction, he maintains direct ownership of 479,803 shares, in addition to 2,090 indirect shares held through the Lisette and Michael Farrell Family Trust and 4,993 remaining options.